Magazine Article | December 24, 2014

Janssen Pharmaceuticals R&D Adopts A Venture Capital Innovation Model

Source: Life Science Leader

Faced with diminishing returns on R&D investments, large pharmaceutical companies are searching for innovative ways to successfully identify, develop, and market products with financial viability. Yet small discovery companies and biotechs continue to outpace large pharma in the approval of NMEs (new molecular entities).